We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

PI(4)K Inhibitor Could Prove Cure For Killer Diarrhoea

News   Jun 06, 2017 | Original Story from Novartis

 
A Cryptosporidium PI(4)K Inhibitor is a Drug Candidate for Cryptosporidiosis

Cryptosporidium parvum. Credit: EPA/H.D.A. Lindquist

 
 
Advertisement
 

RELATED ARTICLES

Oxford's COVID-19 Vaccine Has 70% Efficacy Rate

News

There are now over 170 teams of researchers working to develop a vaccine for protection against COVID-19. Over the last few weeks, a number of groups shared interim analysis data on candidates that have reached Phase III clinical testing. The latest addition is the University of Oxford – in collaboration with the pharmaceutical company AstraZeneca – who today announce an efficacy of 70.4% for the candidate, ChAdOx1 nCoV-2019.

READ MORE

Metal-Organic Frameworks Successfully Deliver CRISPR/Cas9 Into Human Cancer Cells

News

Researchers used metal-organic frameworks (MOFs) enhanced with a green tea phytochemical coating to target human prostate cancer cells for the first time.

READ MORE

Folding of SARS-CoV2 Genome Reveals Drug Targets

News

Research alliance has observed the RNA folding structures of the SARS-CoV2 genome with which the virus controls the infection process.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE